MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Regulation FD DisclosureITEM 7.01
REGULATION FD DISCLOSURE
MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Regulation FD Disclosure
On April 2, 2018, MabVax Therapeutics Holdings, Inc. (the “Company”) issued a press release that provided the Company’s 2017 operational and financial results and 2018 milestones. The press release is attached hereto as Exhibit 99.1.
The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
|
ITEM 9.01 |
FINANCIAL STATEMENTS AND EXHIBITS |
(d)Exhibits.
The exhibit listed in the following Exhibit Index is furnished with this Current Report on Form 8-K.
|
Exhibit No. |
Description |
|
Press release issued April 2, 2018 |
MABVAX THERAPEUTICS HOLDINGS, INC. ExhibitEX-99.1 2 ex99-1.htm PRESS RELEASE Blueprint Exhibit 99.1 MabVax Therapeutics Reports 2017 Operational and Financial Results and 2018 Milestones – 2017 marked by clinical advancement of treatments for various cancers – – Management on track to execute value-driving corporate and clinical milestones in the first half of 2018 – – Company expects to complete one or more strategic transactions with third parties that are intended to unlock significant value in 2018 – SAN DIEGO,…To view the full exhibit click here
